Stewart Fisher - Jan 30, 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Jan 30, 2023
Transactions value $
-$10,122
Form type
4
Date filed
2/1/2023, 03:08 PM
Previous filing
Jun 14, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise +3.75K +5.06% 77.8K Jan 30, 2023 Direct F1
transaction CCCC Common Stock Tax liability -$10.1K -1.3K -1.67% $7.78 76.5K Jan 30, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Performance Restricted Stock Units Options Exercise $0 -3.75K -16.67% $0.00 18.8K Jan 30, 2023 Common Stock 3.75K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.